Compare RSSS & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSSS | CRDF |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.2M | 67.1M |
| IPO Year | 2008 | 2012 |
| Metric | RSSS | CRDF |
|---|---|---|
| Price | $2.14 | $0.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $3.75 | ★ $5.14 |
| AVG Volume (30 Days) | 49.9K | ★ 1.0M |
| Earning Date | 11-16-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | 27.37 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $28,793,922.00 | $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.30 | N/A |
| P/E Ratio | $102.50 | ★ N/A |
| Revenue Growth | 2.77 | ★ 49.61 |
| 52 Week Low | $1.77 | $0.71 |
| 52 Week High | $3.38 | $3.31 |
| Indicator | RSSS | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 61.18 | 48.53 |
| Support Level | $1.84 | $0.75 |
| Resistance Level | $2.13 | $1.13 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 57.14 | 67.42 |
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from the cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.